1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Ebola and Marburg Infections - Pipeline Review, H1 2014

Ebola and Marburg Infections - Pipeline Review, H1 2014

  • June 2014
  • -
  • Global Markets Direct
  • -
  • 53 pages

Ebola and Marburg Infections - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Ebola and Marburg Infections - Pipeline Review, H1 2014’, provides an overview of the Ebola and Marburg Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ebola and Marburg Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ebola and Marburg Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Ebola and Marburg Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Ebola and Marburg Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ebola and Marburg Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ebola and Marburg Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ebola and Marburg Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Ebola and Marburg Infections - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Ebola and Marburg Infections Overview 7
Therapeutics Development 8
Pipeline Products for Ebola and Marburg Infections - Overview 8
Pipeline Products for Ebola and Marburg Infections - Comparative Analysis 9
Ebola and Marburg Infections - Therapeutics under Development by Companies 10
Ebola and Marburg Infections - Therapeutics under Investigation by Universities/Institutes 12
Ebola and Marburg Infections - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Ebola and Marburg Infections - Products under Development by Companies 15
Ebola and Marburg Infections - Products under Investigation by Universities/Institutes 16
Ebola and Marburg Infections - Companies Involved in Therapeutics Development 17
GlaxoSmithKline plc 17
Inovio Pharmaceuticals, Inc. 18
Bavarian Nordic A/S 19
Crucell N.V. 20
NanoViricides, Inc. 21
AlphaVax, Inc. 22
Immunovaccine, Inc. 23
Integrated BioTherapeutics, Inc. 24
Profectus BioSciences, Inc. 25
Mapp Biopharmaceutical, Inc. 26
Ebola and Marburg Infections - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Combination Products 28
Assessment by Target 29
Assessment by Mechanism of Action 30
Assessment by Route of Administration 31
Assessment by Molecule Type 32
Drug Profiles 34
Vaccine for Multivalent Filovirus - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Ebola Vaccine + Marburg Vaccine - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Vaccine For Filovirus - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Ebola/Marburg Program - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
Ebola And Marburg Vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Monoclonal Antibody for Marburg Virus - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Polyvalent DNA Vaccine for Ebola and Marburg Filoviruses - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
MVA-BN-Filoviruses Vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
rVSV-Vectored Vaccines - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
Subunit Vaccine for Multifiloviruses - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
Monoclonal Antibodies to Inhibit Glycoprotein for Marburg Virus Infection - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
Monoclonal Antibodies for Ebola and Marburg Infections - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
Ebola and Marburg Infections - Recent Pipeline Updates 47
Ebola and Marburg Infections - Dormant Projects 48
Ebola and Marburg Infections - Discontinued Products 49
Ebola and Marburg Infections - Product Development Milestones 50
Featured News and Press Releases 50
Sep 18, 2012: Sarepta Therapeutics's Marburg Drug Receives FDA Fast Track Designation 50
Sep 04, 2012: Sarepta Therapeutics Receives $3.9m Contract From U.S. Government To Evaluate Feasibility Of Alternate Route Of Administration Of AVI-7288 For Treatment Of Marburg Virus 50
Jun 18, 2012: Bavarian Nordic Receives Contract From US Government To Advance Development Of New MVA-BN Based Vaccines 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 53
Disclaimer 53

List of Tables

Number of Products under Development for Ebola and Marburg Infections, H1 2014 8
Number of Products under Development for Ebola and Marburg Infections - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Products under Development by Companies, H1 2014 15
Products under Investigation by Universities/Institutes, H1 2014 16
Ebola and Marburg Infections - Pipeline by GlaxoSmithKline plc, H1 2014 17
Ebola and Marburg Infections - Pipeline by Inovio Pharmaceuticals, Inc., H1 2014 18
Ebola and Marburg Infections - Pipeline by Bavarian Nordic A/S, H1 2014 19
Ebola and Marburg Infections - Pipeline by Crucell N.V., H1 2014 20
Ebola and Marburg Infections - Pipeline by NanoViricides, Inc., H1 2014 21
Ebola and Marburg Infections - Pipeline by AlphaVax, Inc., H1 2014 22
Ebola and Marburg Infections - Pipeline by Immunovaccine, Inc., H1 2014 23
Ebola and Marburg Infections - Pipeline by Integrated BioTherapeutics, Inc., H1 2014 24
Ebola and Marburg Infections - Pipeline by Profectus BioSciences, Inc., H1 2014 25
Ebola and Marburg Infections - Pipeline by Mapp Biopharmaceutical, Inc., H1 2014 26
Assessment by Monotherapy Products, H1 2014 27
Assessment by Combination Products, H1 2014 28
Number of Products by Stage and Target, H1 2014 29
Number of Products by Stage and Mechanism of Action, H1 2014 30
Number of Products by Stage and Route of Administration, H1 2014 31
Number of Products by Stage and Molecule Type, H1 2014 33
Ebola and Marburg Infections Therapeutics - Recent Pipeline Updates, H1 2014 47
Ebola and Marburg Infections - Dormant Projects, H1 2014 48
Ebola and Marburg Infections - Discontinued Products, H1 2014 49

List of Figures

Number of Products under Development for Ebola and Marburg Infections, H1 2014 8
Number of Products under Development for Ebola and Marburg Infections - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Products, H1 2014 14
Assessment by Monotherapy Products, H1 2014 27
Number of Products by Stage and Top 10 Target, H1 2014 29
Number of Products by Stage and Top 10 Route of Administration, H1 2014 31
Number of Products by Top 10 Molecule Type, H1 2014 32
Number of Products by Stage and Top 10 Molecule Type, H1 2014 33

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2017 World Infectious Disease Testing Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies, Opportunities

2017 World Infectious Disease Testing Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies, Opportunities

  • $ 59500
  • Industry report
  • January 2017
  • by Venture Planning Group

This unique 68-country survey from VPGMarketResearch.com provides data and analysis not available from any other published source. The survey is designed to assist diagnostics industry executives, as well ...

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...


Download Unlimited Documents from Trusted Public Sources

Blood Supply Industry in Namibia and Africa

  • February 2017
    209 pages
  • Health Care Pro...  

    Blood Supply  

    HIV AIDS  

  • Namibia  

    Africa  

    World  

View report >

Influenza Statistics

  • February 2017
    119 pages
  • Influenza  

    Hospital  

View report >

HIV AIDS Statistics in South Africa

  • February 2017
    8 pages
  • HIV AIDS  

    Food  

  • South Africa  

View report >

Related Market Segments :

Infectious Disease
Therapy
Monoclonal Antibody

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.